Jessica Atkinson was appointed as Chief Business Officer of VectorY Therapeutics in May 2025. Ms. Atkinson brings over 20 years of experience in business development and commercialization, having held leadership roles at ImmuneID, Glympse Bio, and Foundation Medicine, and worked in the U.S. commercial organization at Merck & Co.

Within VectorY Therapeutics, Ms. Atkinson leads long-term business strategy and strategic partnerships to support the company’s growth and advancement of its neurodegenerative disease pipeline. Prior to joining VectorY, Ms. Atkinson founded and led TwoStep Advisors, advising early-stage biotech companies.

Ms. Atkinson holds a B.S. in Molecular Biology from the University of Texas at Austin and is an active mentor and advocate for women in science.